Videos

We are all citizens of the same planet.

Recent research indicates 6.1 million children, or 3 per classroom, possess the symptoms for an attention-deficit/hyperactivity disorder diagnosis.

Here's why the next step in mental health treatment is digital.

"...They speak in poetry. Do they know I am there, listening?"

Do unto others as you wish them to do unto you: words that are more important than ever.

68% of Americans reported their mental health could be improved.

Addiction to technology: what concerns should you have as a clinician?

"I must go down to the seas again, to the lonely sea and the sky..."

Here's why psychedelics might be a valuable addition to mental health treatment.

Engaging and caring for staff during difficult times will help reduce burnout, increase productivity, and most importantly, sustain happiness.

"The warping night air having brought the boom, Of an owl's voice into her darkened room..."

Kids need someone to raise them with unconditional love...

Caring for yourself does not mean you're ignoring the needs of others.

"Write yourself scared the first day of med school, dying to cure the world..."

Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, give advice to any clinicians considering the use of intranasal esketamine for treatment resistant depression.

Drs Harding and Halaris review the requirements health care settings must follow in order to procure, prescribe, and dispense intranasal esketamine as treatment resistant depression therapy.

Two psychiatrists discuss the importance of intranasal esketamine having a Risk Evaluation and Mitigation Strategy (REMS) and how that impacts treatment for treatment resistant depression.

Drs Harding and Halaris evaluate the phase 3 TRANSFORM trial that studied intranasal esketamine as a therapy option for treatment resistant depression.

Two experts examine the impact of targeting the glutamatergic system as therapy for treatment resistant depression.

Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, discuss their thoughts on starting treatment with intransal esketamine and what to expect.

Two psychiatrists review the case of 42-year-old female patient with a treatment resistant depression diagnosis that was prescribed intranasal esketamine.

Drs Harding and Halaris provide an overview of treatment resistant depression, including prevalence and determining a diagnosis.

Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, review a case of a 26-year-old male patient who was recently diagnosed with treatment resistant depression

How long do marriages last? What about love?

Michael E. Thase, MD; Theresa Cerulli, MD; Gustavo Alva, MD, DFAPA; and Tina Matthews-Hayes, DNP, FNP, PMHNP, provide insight on the role of telemedicine in improving outcomes for patients with bipolar disorder.

A panel of experts in psychiatry consider the use of a novel second-generation antipsychotic for the management of treatment resistant depression.

Michael E. Thase, MD, presents the case of a 47-year-old man with treatment resistant bipolar depression.

Psychiatric experts consider mood stabilizers when treating bipolar disorder and review the role of antidepressants in disease management.

Theresa Cerulli, MD, and Tina Matthew-Hayes, DNP, FNP, PMHNP, review diagnostic difficulties of the patient’s primary care physician in patient case #1 and share optimal approaches to the diagnosis and treatment for patients with bipolar disorder.

Tina Matthews-Hayes, DNP, FNP, PMHNP, comments on screening tools for bipolar disorder and Gustavo Alva, MD, DFAPA, shares his impressions from patient case #1.